ArticleEuropean journal of drug metabolism and pharmacokinetics2026
Personalizing Liposomal Paclitaxel in Platinum-Based Combination Therapy for Gynecologic Cancers: Defining a Therapeutic Window Based on Tc
Article in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
objectiveCurrent body surface area (BSA)-based dosing of liposomal paclitaxel (L-PTX) fails to account for substantial interpatient variability in drug exposure, leading to inconsistent therapeutic outcomes. This study investigated the relationships between L-PTX pharmacokinetic exposure (quantified as time above threshold concentration [Tc MATERIALS AND
methodsWe conducted a study of 85 patients with gynecological tumors receiving platinum-based combination therapy with L-PTX (September 2020-January 2023). Plasma concentrations of paclitaxel and its metabolite 6α-hydrpaclitaxel (6α-OHP) were measured 20-22 h post-infusion using validated ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) methods. Tc
resultsL-PTX Tc
conclusionsBSA-based L-PTX dosing inadequately addresses pharmacokinetic variability. We demonstrate that Tc
Indexed as
Identifiers
42047943What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.